Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Assets (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Current Assets for 4 consecutive years, with $229.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 36.42% to $229.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $229.0 million through Dec 2025, down 36.42% year-over-year, with the annual reading at $229.0 million for FY2025, 36.42% down from the prior year.
  • Current Assets for Q4 2025 was $229.0 million at Phathom Pharmaceuticals, up from $207.8 million in the prior quarter.
  • The five-year high for Current Assets was $397.4 million in Q4 2023, with the low at $139.8 million in Q1 2023.
  • Average Current Assets over 4 years is $252.2 million, with a median of $227.8 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 147.6% in 2023, then crashed 44.42% in 2025.
  • Over 4 years, Current Assets stood at $160.5 million in 2022, then soared by 147.6% to $397.4 million in 2023, then fell by 9.38% to $360.1 million in 2024, then tumbled by 36.42% to $229.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $229.0 million, $207.8 million, and $218.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.